Coastal Investment Advisors, Inc. Outlook Therapeutics, Inc. Transaction History

Coastal Investment Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.91 - $2.01 $10,010 - $22,109	-11,000 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$1.27 - $2.23 $6,350 - $11,150	-5,000 Reduced 31.25%	11,000 $15,000
Q3 2021 Oct 18, 2021	BUY	$2.12 - $2.76 $10,600 - $13,799	5,000 Added 45.45%	16,000 $35,000
Q2 2021 Jul 15, 2021	SELL	$1.78 - $2.76 $1,780 - $2,760	-1,000 Reduced 8.33%	11,000 $27,000
Q1 2021 Apr 12, 2021	SELL	$0.94 - $3.31 $2,820 - $9,930	-3,000 Reduced 20.0%	12,000 $27,000

Q4 2020 Jan 13, 2021	BUY	$0.7 - $1.58 $3,500 - $7,900	5,000 Added 50.0%	15,000 $20,000
Q2 2020 Jul 16, 2020	BUY	$0.56 - $1.41 $5,600 - $14,100	10,000 New	10,000 $13,000
Q1 2020 Apr 23, 2020	SELL	$0.51 - $1.08 $2,550 - $5,400	-5,000 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$0.91 - $7.68 $3,412 - $28,800	3,750 Added 300.0%	5,000 $10,000
Q1 2019 May 15, 2019	BUY	$4.26 - $10.56 $5,325 - $13,200	1,250 New	1,250 $9,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.6B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Coastal Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Coastal Investment Advisors, Inc. with notifications on news.